{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:37:36Z","timestamp":1772606256190,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P30CA196521"],"award-info":[{"award-number":["5P30CA196521"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10549-025-07802-7","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T11:43:39Z","timestamp":1755344619000},"page":"159-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer"],"prefix":"10.1007","volume":"214","author":[{"given":"Rima","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jami","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Moshier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hulya","family":"Kocyigit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weronika","family":"Bucwinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao Y.","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupama","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarti","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wilck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Tiersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"issue":"20","key":"7802_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938\u20131948","journal-title":"N Engl J Med"},{"issue":"2","key":"7802_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L (2022) Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs. Nat Rev Clin Oncol 19(2):91\u2013113","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"7802_CR3","first-page":"524","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL (2022) Breast cancer statistics, 2022. CA Cancer J Clin 72(6):524\u2013541","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"7802_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H et al (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387(3):217\u2013226","journal-title":"N Engl J Med"},{"issue":"16","key":"7802_CR5","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384(16):1529\u20131541","journal-title":"N Engl J Med"},{"key":"7802_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.breast.2023.01.005","volume":"67","author":"I Schlam","year":"2023","unstructured":"Schlam I, Tolaney SM, Tarantino P (2023) How i treat HER2-low advanced breast cancer. Breast 67:116\u2013123","journal-title":"Breast"},{"issue":"3","key":"7802_CR7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s10549-012-2008-6","volume":"133","author":"A Brufsky","year":"2012","unstructured":"Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N, Yardley DA (2012) Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 133(3):1067\u20131075","journal-title":"Breast Cancer Res Treat"},{"key":"7802_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10549-010-0824-0","volume":"121","author":"EA Perez","year":"2010","unstructured":"Perez EA, Patel T, Moreno-Aspitia A (2010) Efficacy of ixabepilone in ER\/PR\/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 121:261\u2013271","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"7802_CR9","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/annonc\/mdw203","volume":"27","author":"X Pivot","year":"2016","unstructured":"Pivot X, Marm\u00e9 F, Koenigsberg R, Guo M, Berrak E, Wolfer A (2016) Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 27(8):1525\u20131531","journal-title":"Ann Oncol"},{"issue":"26","key":"7802_CR10","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","volume":"26","author":"DP Atchley","year":"2008","unstructured":"Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282\u20134288","journal-title":"J Clin Oncol"},{"issue":"35","key":"7802_CR11","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1200\/JCO.2012.44.5635","volume":"30","author":"N Tung","year":"2012","unstructured":"Tung N, Garber JE, Lincoln A, Domchek SM (2012) Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations. J Clin Oncol 30(35):4447\u20134448","journal-title":"J Clin Oncol"},{"issue":"4","key":"7802_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.coph.2005.03.006","volume":"5","author":"N Turner","year":"2005","unstructured":"Turner N, Tutt A, Ashworth A (2005) Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 5(4):388\u2013393","journal-title":"Curr Opin Pharmacol"},{"issue":"7035","key":"7802_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917\u2013921","journal-title":"Nature"},{"key":"7802_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr3231","volume":"14","author":"T Byrski","year":"2012","unstructured":"Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, Cybulski C, Marczyk E, Chrzan R, Eisen A (2012) Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 14:1\u20138","journal-title":"Breast Cancer Res"},{"issue":"4","key":"7802_CR15","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/annonc\/mdq461","volume":"22","author":"L Staudacher","year":"2011","unstructured":"Staudacher L, Cottu P, Dieras V, Vincent-Salomon A, Guilhaume M, Escalup L, Dorval T, Beuzeboc P, Mignot L, Pierga J (2011) Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 22(4):848\u2013856","journal-title":"Ann Oncol"},{"issue":"1","key":"7802_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1179\/joc.2011.23.1.40","volume":"23","author":"R Maisano","year":"2011","unstructured":"Maisano R, Zavettieri M, Azzarello D, Raffaele M, Maisano M, Bottari M, Nardi M (2011) Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline-and taxane-pretreated breast cancer patients: a phase II study. J Chemother 23(1):40\u201343","journal-title":"J Chemother"},{"issue":"5573","key":"7802_CR17","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573):1655\u20131657","journal-title":"Science"},{"key":"7802_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr3557","volume":"15","author":"E Karlsson","year":"2013","unstructured":"Karlsson E, P\u00e9rez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, Sgroi DC, Nordenskj\u00f6ld B, Hallbeck A-L, St\u00e5l O (2013) The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res 15:1\u201314","journal-title":"Breast Cancer Res"},{"issue":"5","key":"7802_CR19","doi-asserted-by":"publisher","first-page":"638","DOI":"10.4161\/epi.6.5.15667","volume":"6","author":"OA Stefansson","year":"2011","unstructured":"Stefansson OA, Jonasson JG, Olafsdottir K, Hilmarsdottir H, Olafsdottir G, Esteller M, Johannsson OT, Eyfjord JE (2011) CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal\/triple-negative breast cancer. Epigenetics 6(5):638\u2013649","journal-title":"Epigenetics"},{"issue":"5","key":"7802_CR20","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/bjc.2013.31","volume":"108","author":"F Zagouri","year":"2013","unstructured":"Zagouri F, Bago-Horvath Z, R\u00f6ssler F, Brandstetter A, Bartsch R, Papadimitriou C, Dimitrakakis C, Tsigginou A, Papaspyrou I, Giannos A (2013) High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 108(5):1100\u20131105","journal-title":"Br J Cancer"},{"key":"7802_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-013-0801-7","volume":"31","author":"M Inanc","year":"2014","unstructured":"Inanc M, Ozkan M, Karaca H, Berk V, Bozkurt O, Duran AO, Ozaslan E, Akgun H, Tekelioglu F, Elmali F (2014) Cytokeratin 5\/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol 31:1\u20138","journal-title":"Med Oncol"},{"issue":"10","key":"7802_CR22","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30(10):870\u2013884","journal-title":"Adv Ther"},{"issue":"9","key":"7802_CR23","first-page":"2713","volume":"31","author":"H Liu","year":"2011","unstructured":"Liu H, Zang C, Schefe J-H, Schwarzlose-Schwarck S, Regierer A-C, Elstner E, Schulz C-O, Scholz C, Possinger K, Eucker J (2011) The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Anticancer Res 31(9):2713\u20132722","journal-title":"Anticancer Res"},{"issue":"9","key":"7802_CR24","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/j.1349-7006.2012.02359.x","volume":"103","author":"M Yunokawa","year":"2012","unstructured":"Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M, Masutomi K (2012) Efficacy of everolimus, a novel m TOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci 103(9):1665\u20131671","journal-title":"Cancer Sci"},{"issue":"15","key":"7802_CR25","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-16-3055","volume":"23","author":"B Jovanovi\u0107","year":"2017","unstructured":"Jovanovi\u0107 B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM et al (2017) A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II\/III triple-negative breast cancer (TNBC): responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67. Clin Cancer Res 23(15):4035\u20134045","journal-title":"Clin Cancer Res"},{"issue":"8","key":"7802_CR26","first-page":"3435","volume":"32","author":"S Schwarzlose-Schwarck","year":"2012","unstructured":"Schwarzlose-Schwarck S, Scholz CW, Regierer AC, Martus P, Neumann C, Habbel P, Liu H, Zang C, Schefe J-H, Schulz C-O (2012) The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer\u2013a phase I trial. Anticancer Res 32(8):3435\u20133441","journal-title":"Anticancer Res"},{"issue":"2","key":"7802_CR27","doi-asserted-by":"publisher","first-page":"R32","DOI":"10.1186\/bcr3634","volume":"16","author":"JC Singh","year":"2014","unstructured":"Singh JC, Novik Y, Stein S, Volm M, Meyers M, Smith J, Omene C, Speyer J, Schneider R, Jhaveri K et al (2014) Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res 16(2):R32","journal-title":"Breast Cancer Res"},{"key":"7802_CR28","unstructured":"Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics [https:\/\/www.fda.gov\/media\/71195\/download]"},{"key":"7802_CR29","unstructured":"NCCN Clinical Practice Guidelines in Oncology Breast Cancer [https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf]"},{"issue":"5","key":"7802_CR30","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P et al (2018) Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med 24(5):628\u2013637","journal-title":"Nat Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07802-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07802-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07802-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T07:10:00Z","timestamp":1758784200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07802-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7802"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07802-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.T. reports a consulting\/advisory role for Puma Biotechnology, Immunomedics, AstraZeneca, Novartis, eisai and Roche\/Genentech. All other authors report no relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The protocol was approved by the Icahn School of Medicine at Mount Sinai\u2019s Institutional Review Boards and conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}